Intra-Cellular Therapies Inc. (NASDAQ:ITCI) went up by 3.13% during the previous trading session, and it is maintaining the win ahead of Wednesday’s trading session. The share price of the Biotechnology giant went up by $25.05 to trade ended Wednesday trading at $24.29. This is up from the $24.29 price recorded on Tuesday’s trading session. Thanks to this latest performance, ITCI is closer to the higher price 52-week target of $70.00 and further from the lowest price target of $32.00. Its performance from the start of the year has also been negative, with ITCI down by -26.99% year-to-date.
Intra-Cellular Therapies Inc. (ITCI) started the day trading at $24.55 and recorded an intraday high of $25.3. It also recorded an intraday low of $24.39 during Wednesday’s trading session. Intra-Cellular Therapies Inc. is a very active stock that recorded a trading volume that is less than -42.25% of the average daily trading volume on Wednesday. The stock’s trading volume on Wednesday was 612378, which is less than -42.25 of the total average daily trading volume of 871.08K.
Intra-Cellular Therapies Inc. (NASDAQ:ITCI) 2020 Performance Impressive
The increase in ITCI’s stock price on Wednesday saw its overall performance boost over the past few months. We can quantify the performance of the stock so far this year using a few metrics. The 52-week high price of ITCI currently stands at $43.56, which is higher than the current trading price of the stock by 42.49%. However, ITCI’s current trading price is -271.11% lower than the 52-week low price of $6.75. In terms of trading volume, Intra-Cellular Therapies Inc. currently experienced healthy participation during the last trading session. 612378 shares of Intra-Cellular Therapies Inc. were traded on the stock exchange on Wednesday, which is less than -42.25% of the 871.08K average trading volume of the stock.
The performance of the stock has been positive over the past year. ITCI’s performance over the past one year has seen it surge by 120.12%, while the stock has gone down by -19.19% in the last six months. The quarterly performance of ITCI currently stands at 63.83%, and it is up by 11.98% in the last month. The only negative figure was from the weekly performance, which currently reads -2.42%. At the time of writing ITCI’s report, the company has a total market cap of $1.73B, making it one of the largest publicly-traded companies in the world.Intra-Cellular Therapies Inc. also has over 330 employees all over the world.
ITCI Insider Activities
For Intra-Cellular Therapies Inc., insiders hold 79.40% of all company shares. The insider transactions over the past six months are down by -0.60%. During that period, insiders bought 92,672 shares in 14 transactions. In that same period, insiders sold 87,340 of their shares in 7 transactions. After these transactions, insiders at Intra-Cellular Therapies Inc. now hold 4.03M shares, which is over 69.59% of the total company stocks. Institutional investors currently hold a large chunk of the ITCI shares, as they control 6.07% of the company’s total stock.
ITCI Fundamental Analysis
For Intra-Cellular Therapies Inc., the stock’s diluted earnings per share (EPS) stands at -2.77. In the coming year, analysts expect the EPS to be -2.69. The stock’s EPS growth this year is 5.60%, -20.10% in the previous five years. In terms of revenue, Intra-Cellular Therapies Inc.’s quarterly sales (YOY) is shrinking at -0.91, which is higher than the average annual revenue of -20.10% over the past half a decade.
The gross margin of the company is 93.90%.
ITCI Analysts Prediction
Another analyst that has a Buy rating for ITCI is Canaccord Genuity, which set a price target of between $29 and $65.
Three analysts, JP Morgan, Cantor Fitzgerald, and Piper Jaffray, all rate the stock as overweight.
ITCI Technical Analysis
The Simple Moving Average (SMA) is one of the most powerful technical indicators. The 20-day Simple Moving Average of ITCI currently stands at 4.64%, while the SMA50 is 14.45%. The biggest one is the SMA200, which is currently reading 41.41% ahead of Wednesday’s trading session. The Relative Strength Index of this stock is 57.77.
